GlassScriptPhysician profile
Cindy Fen Chang
NPI 1316561236
$14,202.69
in general payments reported to CMS, 2019-2025
38 companies · $3,259 in 2025
The $3,259 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,883 · 2022: $2,407 · 2023: $2,909 · 2024: $2,745 · 2025: $3,259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,877 · Education: $35.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,877.42 |
| Education | $35.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,308.73 | 2021-2025 | |
| Janssen Biotech, INC. | $1,432.40 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,090.91 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Celgene Corporation | $734.77 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $707.34 | 2021-2025 | Entyvio, Eohilia |
| Nestle Healthcare Nutrition INC. | $607.97 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $585.75 | 2024-2025 | Vowst, Zenpep |
| Gilead Sciences, INC. | $524.90 | 2021-2025 | |
| Genzyme Corporation | $518.70 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $445.74 | 2021-2025 | Ocaliva |
| Janssen Scientific Affairs, LLC | $334.20 | 2021-2022 | |
| Ardelyx, INC. | $291.10 | 2024-2025 | Ibsrela |
| Redhill Biopharma INC. | $271.79 | 2021-2023 | Movantik, Talicia, Aemcolo |
| Madrigal Pharmaceuticals | $264.59 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $221.90 | 2024-2025 | Iqirvo |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $216.70 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $155.44 | 2021-2024 | Linzess |
| Merck Sharp & Dohme LLC | $152.65 | 2021-2024 | Dificid |
| Teva Pharmaceuticals USA, INC. | $134.09 | 2022 | |
| Ferring Pharmaceuticals INC. | $131.57 | 2021-2023 | Rebyota |
| Genentech USA, INC. | $125.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $122.87 | 2021 | |
| Ethicon US, LLC | $120.72 | 2021-2024 | Linx Reflux Management System |
| Braintree Laboratories, INC. | $105.61 | 2021-2025 | Sutab, Suflave |
| Phathom Pharmaceuticals, INC. | $91.71 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $90.33 | 2023 | Breztri |
| Pfizer INC. | $68.37 | 2023-2025 | |
| Qol Medical, LLC | $50.52 | 2022 | |
| Biocon Biologics INC | $43.69 | 2025 | Yesintek |
| Exact Sciences Corporation | $42.73 | 2023-2025 | The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $38.33 | 2025 | Wegovy |
| Celltrion USA INC. | $36.86 | 2024 | Vegzelma |
| Organon LLC | $29.66 | 2023-2025 | Renflexis, Hadlima |
| Evoke Pharma, INC. | $27.89 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $26.25 | 2025 | Orgovyx |
| Lilly USA, LLC | $19.94 | 2025 | Omvoh |
| Digestive Care, INC. | $16.04 | 2025 | Pertzye |
| Lucid Diagnostics INC. | $14.93 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.